Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

63 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Using a Modified Delphi Panel to Estimate Health Service Utilization for Patients with Advanced and Non-Advanced Systemic Light Chain Amyloidosis.
Gertz M, Abonour R, Gibbs SN, Finkel M, Landau H, Lentzsch S, Lin G, Mahindra A, Quock T, Rosenbaum C, Rosenzweig M, Sidana S, Tuchman SA, Witteles R, Yermilov I, Broder MS. Gertz M, et al. Among authors: tuchman sa. Clinicoecon Outcomes Res. 2023 Sep 11;15:673-680. doi: 10.2147/CEOR.S412079. eCollection 2023. Clinicoecon Outcomes Res. 2023. PMID: 37719133 Free PMC article.
Characterizing the developmental pathways TTF-1, NKX2-8, and PAX9 in lung cancer.
Hsu DS, Acharya CR, Balakumaran BS, Riedel RF, Kim MK, Stevenson M, Tuchman S, Mukherjee S, Barry W, Dressman HK, Nevins JR, Powers S, Mu D, Potti A. Hsu DS, et al. Proc Natl Acad Sci U S A. 2009 Mar 31;106(13):5312-7. doi: 10.1073/pnas.0900827106. Epub 2009 Mar 11. Proc Natl Acad Sci U S A. 2009. PMID: 19279207 Free PMC article.
Phase I study of opaganib, an oral sphingosine kinase 2-specific inhibitor, in relapsed and/or refractory multiple myeloma.
Kang Y, Sundaramoorthy P, Gasparetto C, Feinberg D, Fan S, Long G, Sellars E, Garrett A, Tuchman SA, Reeves BN, Li Z, Liu B, Ogretmen B, Maines L, Ben-Yair VK, Smith C, Plasse T. Kang Y, et al. Among authors: tuchman sa. Ann Hematol. 2023 Feb;102(2):369-383. doi: 10.1007/s00277-022-05056-7. Epub 2022 Dec 3. Ann Hematol. 2023. PMID: 36460794 Clinical Trial.
Gene expression profiles of tumor biology provide a novel approach to prognosis and may guide the selection of therapeutic targets in multiple myeloma.
Anguiano A, Tuchman SA, Acharya C, Salter K, Gasparetto C, Zhan F, Dhodapkar M, Nevins J, Barlogie B, Shaughnessy JD Jr, Potti A. Anguiano A, et al. Among authors: tuchman sa. J Clin Oncol. 2009 Sep 1;27(25):4197-203. doi: 10.1200/JCO.2008.19.1916. Epub 2009 Jul 27. J Clin Oncol. 2009. PMID: 19636021 Free PMC article.
Risk stratification, treatment selection, and transplant eligibility in multiple myeloma: a qualitative study of the perspectives and self-reported practices of oncologists.
LeBlanc TW, Howson A, Turell W, Sheldon P, Locke SC, Tuchman SA, Gasparetto C, Kaura S, Khan ZM, Abernethy AP. LeBlanc TW, et al. Among authors: tuchman sa. Curr Oncol. 2016 Dec;23(6):e598-e604. doi: 10.3747/co.23.3298. Epub 2016 Dec 21. Curr Oncol. 2016. PMID: 28050150 Free PMC article.
63 results